Latest Posts:
Search for:
Tag

pricing and reimbursement

Browsing
In EU Pharmaceutical Package

New German Pharmaceutical Strategy Promises to Bolster Investment and Innovation, Implicitly Questioning the EU Pharmaceutical Review

by 6 Mins Read

On 13 December 2023, the German government published a long-awaited strategy outline of intended upcoming legislative measures to counter both the dwindling significance of Germany as a strong hub for pharmaceutical innovation, and threats to supply chain security. The proposed action items fall into 8 chapters, the most significant of which for pharmaceutical companies are briefly summarised below: 1. Strengthening clinical research; a model clinical trial agreement and centralised ethics committee The government intends to…

Read More
In Pharmaceuticals & Biotech

The UK’s Voluntary Scheme for Branded Medicines Pricing and Access rate set to rise (again), to 26.5% for 2023

by , and 3 Mins Read

The UK’s Department of Health and Social Care has announced that the voluntary scheme payment percentage (VPAS) for 2023 will be set at 26.5% of sales for 2023 (representing almost GBP 3.3 billion). This is a further major increase to last year’s VPAS significant rate rise to 15% (around GBP 1.8 billion, rising from GBP 0.6 billion in 2021). VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and…

Read More
In Pharmaceuticals & Biotech

France Proposes Controversial Referencing Procedure for Medicines

by , and 5 Mins Read

In brief The Social Security Financing Bill for 2023 (“Draft Bill”) was introduced on 26 September 2022. It is currently being debated in parliament and is expected to be voted on by the end of 2022. Some of its proposed measures have a potential strong economic impact on health industries and concerns are being raised. In more detail In the context of a permanent increase in the volume of medicines reimbursed by the social security…

Read More